0 Yorumlar
0 hisse senetleri
1K Views
0 önizleme
Site içinde arama yapın
Yeni insanlarla keşfedin, yeni bağlantılar oluşturmak ve yeni arkadaşlar edinmek
-
Please log in to like, share and comment!
-
Natera (NTRA) draws a Buy and a $475 target as Roth/MKM bets on cancer residual disease testsRoth/MKM started coverage of Natera, Inc. (NTRA) at Buy with a $475 target, pointing to wider use of its minimal residual disease blood tests, firmer pricing and a 2027 early detection study readout. Roth/MKM started coverage of Natera, Inc. (NTRA) on Friday, October 23, 2026, with a Buy rating and a $475 price target, Investing.com reported. The firm built its case on the company's cancer...0 Yorumlar 0 hisse senetleri 622 Views 0 önizleme
-
Rare Disease Genetic Testing Market: Next-Generation Genomic Technologies Reshaping HealthcareThe Rare Disease Genetic Testing Market is witnessing significant transformation, shaped by innovation, evolving consumer expectations, regulatory shifts, and global economic trends. Polaris Market Research’s latest report, Rare Disease Genetic Testing Market, offers a holistic view of the market. It examines the market’s structure, growth drivers, competitive landscape,...0 Yorumlar 0 hisse senetleri 2K Views 0 önizleme